All In Biotech

Drug Trial Radar · NCT01472016

Study of ABT-700 in Subjects With Advanced Solid Tumors

A Multi-Center, Phase 1/1b, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

74

Actual

Start

Oct 6, 2011

Primary completion

Apr 27, 2017

Study completion Apr 27, 2017

Sponsor

Lead sponsor
AbbVie (prior sponsor, Abbott)AbbVie (ABBV)
Sponsor type
Industry
First posted
Nov 16, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-700 in subjects with advanced solid tumors that may have MET amplification or c-Met overexpression. ABT-700, previously known as h224G11 in publications, is an anti-c-Met antibody. The early clinical development plan for ABT-700 is based on the activity demonstrated in preclinical models. Up to 124 subjects will be enrolled.

Conditions

  • Advanced Solid Tumors

Interventions

  • ABT-700Drug

    ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.

  • docetaxelDrug

    Docetaxel will be administered by intravenous infusion on Day 1 in 21-day dosing cycles.

  • FOLFIRIDrug

    5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles.

  • cetuximabDrug

    Cetuximab will be administered by intravenous infusion weekly.

  • erlotinibDrug

    Erlotinib will be taken orally daily.

  • ABT-700Drug

    ABT-700 will be administered by intravenous infusion on Day 1 and Day 15 in 28-day dosing cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of ABT-700 when administered as monotherapy and in combination with docetaxel or 5-fluoruracil, folinic acid, irinotecan and cetuximab (FOLFIRI/cetuximab) or erlotinibTime frame: First cycle of treatment through 60 day follow-up visit
  2. To Evaluate the pharmacokinetics of ABT-700 when administered as monotherapy and in combination with docetaxel or 5-fluoruracil, folinic acid, irinotecan and cetuximab (FOLFIRI/cetuximab) or erlotinibTime frame: At each cycle of treatment through 60 days after last dose.
  3. To determine the recommended Phase 2 dose for ABT-700Time frame: First cycle of treatment through 60 day follow-up visit

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.